Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Elranatamab”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Not applicableActive Not RecruitingNCT06479954
What this trial is testing

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Pfizer 1
Early research (Phase 1)Looking for participantsNCT05927571
What this trial is testing

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Genentech, Inc. 120
Testing effectiveness (Phase 2)Study completedNCT05228470
What this trial is testing

Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Who this might be right for
ElranatamabMyelomaMultiple Myeloma+8 more
Pfizer 39
Not applicableNot Yet RecruitingNCT07320326
What this trial is testing

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Who this might be right for
TCE-RRMM
Peking University People's Hospital 159
Large-scale testing (Phase 3)Looking for participantsNCT06918002
What this trial is testing

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome 824
Large-scale testing (Phase 3)Looking for participantsNCT05623020
What this trial is testing

Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy

Who this might be right for
Multiple Myeloma
Pfizer 1,116
Testing effectiveness (Phase 2)Study completedNCT05014412
What this trial is testing

Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

Who this might be right for
Multiple Myeloma
Pfizer 86
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06931704
What this trial is testing

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

Who this might be right for
Multiple Myeloma
Nantes University Hospital 176
Testing effectiveness (Phase 2)Looking for participantsNCT06483100
What this trial is testing

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 65
Post-approval studies (Phase 4)Looking for participantsNCT06057402
What this trial is testing

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Pfizer 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07382739
What this trial is testing

Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Who this might be right for
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
M.D. Anderson Cancer Center 34
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Testing effectiveness (Phase 2)Looking for participantsNCT06974786
What this trial is testing

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
SCRI Development Innovations, LLC 100
Early research (Phase 1)Looking for participantsNCT07280013
What this trial is testing

Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma (MM)
C4 Therapeutics, Inc. 60
Not applicableNot Yet RecruitingNCT07391761
What this trial is testing

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

Who this might be right for
Refractory Multiple Myeloma (RRMM)
Pfizer 30
Not applicableNo Longer AvailableNCT05462639
What this trial is testing

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT06569147
What this trial is testing

Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis

Who this might be right for
AL Amyloidosis
Brigham and Women's Hospital 49
Early research (Phase 1)Looking for participantsNCT05675449
What this trial is testing

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 90
Not applicableActive Not RecruitingNCT06581848
What this trial is testing

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Who this might be right for
Multiple Myeloma
Pfizer 150
Early research (Phase 1)Study completedNCT04798586
What this trial is testing

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Pfizer 4
Load More Results